Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.

Romme Christensen J, Komori M, von Essen MR, Ratzer R, Börnsen L, Bielekova B, Sellebjerg F.

Mult Scler. 2018 May 1:1352458518774880. doi: 10.1177/1352458518774880. [Epub ahead of print]

PMID:
29775134
2.

Functional neuroimaging of recovery from motor conversion disorder: A case report.

Dogonowski AM, Andersen KW, Sellebjerg F, Schreiber K, Madsen KH, Siebner HR.

Neuroimage. 2018 Mar 27. pii: S1053-8119(18)30271-4. doi: 10.1016/j.neuroimage.2018.03.061. [Epub ahead of print] Review.

3.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
4.

Progressive multiple sclerosis, cognitive function, and quality of life.

Højsgaard Chow H, Schreiber K, Magyari M, Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzer R, Soelberg Sørensen P, Sellebjerg F.

Brain Behav. 2018 Jan 5;8(2):e00875. doi: 10.1002/brb3.875. eCollection 2018 Feb.

5.

Smoking affects the interferon beta treatment response in multiple sclerosis.

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F, Søndergaard HB.

Neurology. 2018 Feb 13;90(7):e593-e600. doi: 10.1212/WNL.0000000000004949. Epub 2018 Jan 17.

PMID:
29343473
6.

Prediction of natalizumab anti-drug antibodies persistency.

Deisenhammer F, Jank M, Lauren A, Sjödin A, Ryner M, Fogdell-Hahn A, Sievers C, Lindberg R, Jensen PE, Sellebjerg F, Christodoulou L, Birchler M, Pallardy M, Auer M, Liblau R; ABIRISK consortium.

Mult Scler. 2018 Jan 1:1352458517753721. doi: 10.1177/1352458517753721. [Epub ahead of print]

PMID:
29336205
7.

Disability in progressive MS is associated with T2 lesion changes.

Ammitzbøll C, Dyrby TB, Lyksborg M, Schreiber K, Ratzer R, Romme Christensen J, Iversen P, Magyari M, Garde E, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler Relat Disord. 2018 Feb;20:73-77. doi: 10.1016/j.msard.2017.12.010. Epub 2017 Dec 18.

PMID:
29324249
8.

Bone microarchitecture and bone mineral density in multiple sclerosis.

Olsson A, Oturai AB, Søndergaard HB, Sellebjerg F, Oturai PS.

Acta Neurol Scand. 2018 Mar;137(3):363-369. doi: 10.1111/ane.12884. Epub 2017 Dec 21.

PMID:
29270986
9.

Defining active progressive multiple sclerosis.

Sellebjerg F, Börnsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, Hjermind LE, von Essen M, Ratzer RL, Soelberg Sørensen P, Romme Christensen J.

Mult Scler. 2017 Nov;23(13):1727-1735. doi: 10.1177/1352458517726592. Epub 2017 Aug 23.

PMID:
28831853
10.

Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.

Nielsen BR, Ratzer R, Börnsen L, von Essen MR, Christensen JR, Sellebjerg F.

J Neuroimmunol. 2017 Sep 15;310:17-25. doi: 10.1016/j.jneuroim.2017.06.001. Epub 2017 Jun 3.

PMID:
28778440
11.

The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement.

Hedström AK, Katsoulis M, Hössjer O, Bomfim IL, Oturai A, Sondergaard HB, Sellebjerg F, Ullum H, Thørner LW, Gustavsen MW, Harbo HF, Obradovic D, Gianfrancesco MA, Barcellos LF, Schaefer CA, Hillert J, Kockum I, Olsson T, Alfredsson L.

Eur J Epidemiol. 2017 Oct;32(10):909-919. doi: 10.1007/s10654-017-0250-2. Epub 2017 Jun 8.

12.

Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis.

Buhelt S, Ratzer RL, Christensen JR, Börnsen L, Sellebjerg F, Søndergaard HB.

Cytokine. 2017 May;93:15-25. doi: 10.1016/j.cyto.2017.04.024. Epub 2017 May 13.

PMID:
28511943
13.

Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity.

Søndergaard HB, Petersen ER, Magyari M, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2017 Apr;13:25-27. doi: 10.1016/j.msard.2017.01.015. Epub 2017 Jan 31.

PMID:
28427696
14.

Systemic frequencies of T helper 1 and T helper 17 cells in patients with age-related macular degeneration: A case-control study.

Singh A, Subhi Y, Krogh Nielsen M, Falk MK, Matzen SMH, Sellebjerg F, Sørensen TL.

Sci Rep. 2017 Apr 4;7(1):605. doi: 10.1038/s41598-017-00741-4.

15.

Smoking reduces circulating CD26hiCD161hi MAIT cells in healthy individuals and patients with multiple sclerosis.

Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzer R, Romme Nielsen B, Søndergaard HB, von Essen MR, Sellebjerg F.

J Leukoc Biol. 2017 May;101(5):1211-1220. doi: 10.1189/jlb.3A0616-267R. Epub 2017 Feb 8.

PMID:
28179539
16.

Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.

Petersen ER, Søndergaard HB, Oturai AB, Jensen P, Sorensen PS, Sellebjerg F, Börnsen L.

Mult Scler Relat Disord. 2016 Nov;10:66-72. doi: 10.1016/j.msard.2016.09.001. Epub 2016 Sep 6.

PMID:
27919501
17.

Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Nov;10:169-173. doi: 10.1016/j.msard.2016.10.005. Epub 2016 Oct 26.

PMID:
27919484
18.

Early safety and efficacy of fingolimod treatment in Denmark.

Voldsgaard A, Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2017 Jan;135(1):129-133. doi: 10.1111/ane.12573. Epub 2016 Mar 8.

PMID:
27910101
19.

Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease.

Vinther-Jensen T, Börnsen L, Budtz-Jørgensen E, Ammitzbøll C, Larsen IU, Hjermind LE, Sellebjerg F, Nielsen JE.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6):e287. eCollection 2016 Dec.

20.

Shift work at young age is associated with increased risk of multiple sclerosis in a Danish population.

Gustavsen S, Søndergaard HB, Oturai DB, Laursen B, Laursen JH, Magyari M, Ullum H, Larsen MH, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Sep;9:104-9. doi: 10.1016/j.msard.2016.06.010. Epub 2016 Jun 27.

PMID:
27645354
21.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

22.

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.

Schreiber K, Magyari M, Sellebjerg F, Iversen P, Garde E, Madsen CG, Börnsen L, Romme Christensen J, Ratzer R, Siebner HR, Laursen B, Soelberg Sorensen P.

Mult Scler. 2017 Apr;23(5):675-685. doi: 10.1177/1352458516661048. Epub 2016 Aug 5.

PMID:
27481206
23.

Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.

Lam MA, Maghzal GJ, Khademi M, Piehl F, Ratzer R, Romme Christensen J, Sellebjerg FT, Olsson T, Stocker R.

Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(4):e256. doi: 10.1212/NXI.0000000000000256. eCollection 2016 Aug.

24.

Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.

Soelberg Sorensen P, Sellebjerg F.

Mult Scler. 2016 Aug;22(9):1112-3. doi: 10.1177/1352458516658560. Epub 2016 Jun 30. No abstract available.

PMID:
27364323
25.

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.

Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P.

Mult Scler. 2017 Feb;23(2):234-241. doi: 10.1177/1352458516643393. Epub 2016 Jul 11.

PMID:
27055806
26.

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.

Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D.

Mult Scler. 2017 Jan;23(1):94-105. doi: 10.1177/1352458516638941. Epub 2016 Jul 11.

PMID:
27003945
27.

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr.

28.

Human pegivirus detected in a patient with severe encephalitis using a metagenomic pan-virus array.

Fridholm H, Østergaard Sørensen L, Rosenstierne MW, Nielsen H, Sellebjerg F, Bengård Andersen Å, Fomsgaard A.

J Clin Virol. 2016 Apr;77:5-8. doi: 10.1016/j.jcv.2016.01.013. Epub 2016 Jan 29. Review.

PMID:
26872326
29.

Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis.

Møllgaard M, Degn M, Sellebjerg F, Frederiksen JL, Modvig S.

Eur J Neurol. 2016 May;23(5):898-905. doi: 10.1111/ene.12960. Epub 2016 Feb 12.

PMID:
26872061
30.

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.

Sørensen PS, Sellebjerg F, Lycke J, Färkkilä M, Créange A, Lund CG, Schluep M, Frederiksen JL, Stenager E, Pfleger C, Garde E, Kinnunen E, Marhardt K; RECYCLINE Study Investigators.

Eur J Neurol. 2016 May;23(5):861-70. doi: 10.1111/ene.12953. Epub 2016 Feb 5.

PMID:
26848561
31.

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Sellebjerg F, Cadavid D, Steiner D, Villar LM, Reynolds R, Mikol D.

Ther Adv Neurol Disord. 2016 Jan;9(1):31-43. doi: 10.1177/1756285615615257. Review.

32.

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.

Al Nimer F, Elliott C, Bergman J, Khademi M, Dring AM, Aeinehband S, Bergenheim T, Romme Christensen J, Sellebjerg F, Svenningsson A, Linington C, Olsson T, Piehl F.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 7;3(1):e191. doi: 10.1212/NXI.0000000000000191. eCollection 2016 Feb.

33.
34.

Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.

Dreyer L, Magyari M, Laursen B, Cordtz R, Sellebjerg F, Locht H.

Ann Rheum Dis. 2016 Apr;75(4):785-6. doi: 10.1136/annrheumdis-2015-208490. Epub 2015 Dec 23. No abstract available.

PMID:
26698850
35.

Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis.

Dogonowski AM, Blinkenberg M, Paulson OB, Sellebjerg F, Sørensen PS, Siebner HR, Madsen KH.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):912-4. doi: 10.1136/jnnp-2015-311375. Epub 2015 Dec 14. No abstract available.

36.

Association between age at onset of multiple sclerosis and vitamin D level-related factors.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Neurology. 2016 Jan 5;86(1):88-93. doi: 10.1212/WNL.0000000000002075. Epub 2015 Oct 7.

PMID:
26446064
37.

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Iversen P, Börnsen L, Dyrby TB, Romme Christensen J, Ammitzbøll C, Madsen CG, Garde E, Lyksborg M, Andersen B, Hyldstrup L, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler. 2016 Jun;22(7):926-34. doi: 10.1177/1352458515605908. Epub 2015 Oct 2.

PMID:
26432857
38.

Identification of Suitable Reference Genes for Peripheral Blood Mononuclear Cell Subset Studies in Multiple Sclerosis.

Oturai DB, Søndergaard HB, Börnsen L, Sellebjerg F, Christensen JR.

Scand J Immunol. 2016 Jan;83(1):72-80. doi: 10.1111/sji.12391.

39.

Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis.

Modvig S, Degn M, Sander B, Horwitz H, Wanscher B, Sellebjerg F, Frederiksen JL.

Mult Scler. 2016 Apr;22(5):590-8. doi: 10.1177/1352458515599074. Epub 2015 Aug 17.

PMID:
26283696
40.

Multiple sclerosis: A clinically useful genetic variant in multiple sclerosis?

Sellebjerg F, Oturai AB.

Nat Rev Neurol. 2015 Jul;11(7):371-2. doi: 10.1038/nrneurol.2015.103. Epub 2015 Jun 16. No abstract available.

PMID:
26077840
41.

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.

Börnsen L, Romme Christensen J, Ratzer R, Hedegaard C, Søndergaard HB, Krakauer M, Hesse D, Nielsen CH, Sorensen PS, Sellebjerg F.

PLoS One. 2015 Mar 4;10(3):e0118830. doi: 10.1371/journal.pone.0118830. eCollection 2015.

42.

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect.

Voldsgaard A, Bager P, Garde E, Åkeson P, Leffers AM, Madsen CG, Kapel C, Roepstorff A, Thamsborg SM, Melbye M, Siebner H, Søndergaard HB, Sellebjerg F, Sørensen PS.

Mult Scler. 2015 Nov;21(13):1723-9. doi: 10.1177/1352458514568173. Epub 2015 Feb 19.

PMID:
25698173
43.

Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.

Modvig S, Degn M, Roed H, Sørensen TL, Larsson HB, Langkilde AR, Frederiksen JL, Sellebjerg F.

Mult Scler. 2015 Dec;21(14):1761-70. doi: 10.1177/1352458515574148. Epub 2015 Feb 19.

PMID:
25698172
44.

Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.

Goris A, Pauwels I, Gustavsen MW, van Son B, Hilven K, Bos SD, Celius EG, Berg-Hansen P, Aarseth J, Myhr KM, D'Alfonso S, Barizzone N, Leone MA, Martinelli Boneschi F, Sorosina M, Liberatore G, Kockum I, Olsson T, Hillert J, Alfredsson L, Bedri SK, Hemmer B, Buck D, Berthele A, Knier B, Biberacher V, van Pesch V, Sindic C, Bang Oturai A, Søndergaard HB, Sellebjerg F, Jensen PE, Comabella M, Montalban X, Pérez-Boza J, Malhotra S, Lechner-Scott J, Broadley S, Slee M, Taylor B, Kermode AG, Gourraud PA; International Multiple Sclerosis Genetics Consortium, Sawcer SJ, Andreassen BK, Dubois B, Harbo HF.

Brain. 2015 Mar;138(Pt 3):632-43. doi: 10.1093/brain/awu405. Epub 2015 Jan 22.

45.

Therapeutic interference with leukocyte recirculation in multiple sclerosis.

Sellebjerg F, Sørensen PS.

Eur J Neurol. 2015 Mar;22(3):434-42. doi: 10.1111/ene.12668. Epub 2015 Jan 13. Review.

PMID:
25582213
46.

Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis.

Laursen JH, Søndergaard HB, Albrechtsen A, Frikke-Schmidt R, Koch-Henriksen N, Soelberg Sørensen P, Sellebjerg F, Oturai A.

Mult Scler. 2015 Oct;21(11):1414-22. doi: 10.1177/1352458514563590. Epub 2014 Dec 22.

PMID:
25533295
47.

Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis.

Ratzer R, Romme Christensen J, Romme Nielsen B, Sørensen PS, Börnsen L, Sellebjerg F.

J Neuroimmunol. 2014 Nov 15;276(1-2):195-201. doi: 10.1016/j.jneuroim.2014.08.623. Epub 2014 Aug 30.

PMID:
25218212
48.

Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general.

Gustavsen MW, Viken MK, Celius EG, Berge T, Mero IL, Berg-Hansen P, Aarseth JH, Myhr KM, Søndergaard HB, Sellebjerg F, Oturai AB, Hillert J, Alfredsson L, Olsson T, Kockum I, Lie BA, Harbo HF.

J Neuroimmunol. 2014 Sep 15;274(1-2):174-9. doi: 10.1016/j.jneuroim.2014.06.024. Epub 2014 Jul 6.

PMID:
25037176
49.

CLIPPERS among patients diagnosed with non-specific CNS neuroinflammatory diseases.

Kerrn-Jespersen BM, Lindelof M, Illes Z, Blaabjerg M, Lund EL, Klausen C, Christiansen I, Sellebjerg F, Kondziella D.

J Neurol Sci. 2014 Aug 15;343(1-2):224-7. doi: 10.1016/j.jns.2014.06.002. Epub 2014 Jun 11.

PMID:
24954086
50.

Prediction of response to interferon therapy in multiple sclerosis.

Sellebjerg F, Søndergaard HB, Koch-Henriksen N, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2014 Oct;130(4):268-75. doi: 10.1111/ane.12269. Epub 2014 Jun 18.

PMID:
24943672

Supplemental Content

Loading ...
Support Center